Considerations for Cost-Effectiveness Analysis in Oncology

Jul 1, 2021, 00:00
10.1016/j.jval.2020.12.024
https://www.valueinhealthjournal.com/article/S1098-3015(21)00160-1/fulltext
Title : Considerations for Cost-Effectiveness Analysis in Oncology
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00160-1&doi=10.1016/j.jval.2020.12.024
First page : 1084
Section Title : LETTERS TO THE EDITOR
Open access? : No
Section Order : 1084
In the recent issue of Value in Health, Nguyen et al evaluated the cost-effectiveness of first-line tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML). Using one-year time horizon, the study concluded that generic imatinib is cost-effective relative to other branded TKIs. The authors provide important clinical evidence on the use of TKI in CML, which are as follows: (1) there is no significant difference in overall survival across TKIs indicated for first-line use; (2) treatment with TKIs is generally chronic; and (3) the type of adverse events varies across individual TKIs. Nevertheless, such clinical evidence was not incorporated in their cost-effectiveness analysis and their results are unlikely robust.
Categories :
  • Alternative Medicine
  • Clinical Outcomes
  • Specialized Treatment Areas
Tags :
Regions :
ViH Article Tags :